OBJECTIVES:Artesunate plus amodiaquine is used for malaria treatment in regions with overlapping HIV endemicity. Co-administration of artesunate/amodiaquine with antiretroviral therapy (ART) may result in drug-drug interactions, but minimal data exist. This study evaluated the impact of nevirapine-based ART, containing a backbone of zidovudine and lamivudine, on the disposition of amodiaquine and its active metabolite, desethylamodiaquine (DEAQ). METHODS: This was an open-label, parallel-group pharmacokinetic comparison between HIV-infected, adult subjects receivingsteady-state nevirapine-based ART (n = 10) and ART-naive subjects (control group, n = 11). All subjects received a loose formulation of artesunate/amodiaquine (200/600 mg) daily for 3 days, with serial pharmacokinetic sampling over 96 h following the final dose of artesunate/amodiaquine. Amodiaquine and DEAQ were quantified using a validated HPLC method with UV detection. Pharmacokinetic parameters were determined using standard non-compartmental methods. RESULTS: Exposures to both amodiaquine and DEAQ were significantly lower in the nevirapine-based ART group compared with the control group (amodiaquine AUC₀₋₂₄ 145 versus 204 ng·h/mL, P = 0.02; DEAQ AUC₀₋₉₆ 14,571 versus 21,648 ng·h/mL, P < 0.01). The AUCDEAQ/AUC(amodiaquine) ratio was not different between groups (ART group 116 versus control group 102, P = 0.67). CONCLUSIONS: Subjects on nevirapine-based ART had lower exposure to both amodiaquine and DEAQ (28.9% and 32.7%, respectively). Consequently, this may negatively impact the effectiveness of artesunate/amodiaquine in HIV-infected individuals on this ART combination.
RCT Entities:
OBJECTIVES:Artesunate plus amodiaquine is used for malaria treatment in regions with overlapping HIV endemicity. Co-administration of artesunate/amodiaquine with antiretroviral therapy (ART) may result in drug-drug interactions, but minimal data exist. This study evaluated the impact of nevirapine-based ART, containing a backbone of zidovudine and lamivudine, on the disposition of amodiaquine and its active metabolite, desethylamodiaquine (DEAQ). METHODS: This was an open-label, parallel-group pharmacokinetic comparison between HIV-infected, adult subjects receiving steady-state nevirapine-based ART (n = 10) and ART-naive subjects (control group, n = 11). All subjects received a loose formulation of artesunate/amodiaquine (200/600 mg) daily for 3 days, with serial pharmacokinetic sampling over 96 h following the final dose of artesunate/amodiaquine. Amodiaquine and DEAQ were quantified using a validated HPLC method with UV detection. Pharmacokinetic parameters were determined using standard non-compartmental methods. RESULTS: Exposures to both amodiaquine and DEAQ were significantly lower in the nevirapine-based ART group compared with the control group (amodiaquine AUC₀₋₂₄ 145 versus 204 ng·h/mL, P = 0.02; DEAQ AUC₀₋₉₆ 14,571 versus 21,648 ng·h/mL, P < 0.01). The AUCDEAQ/AUC(amodiaquine) ratio was not different between groups (ART group 116 versus control group 102, P = 0.67). CONCLUSIONS: Subjects on nevirapine-based ART had lower exposure to both amodiaquine and DEAQ (28.9% and 32.7%, respectively). Consequently, this may negatively impact the effectiveness of artesunate/amodiaquine in HIV-infected individuals on this ART combination.
Authors: M J Lamson; J P Sabo; T R MacGregor; J W Pav; L Rowland; A Hawi; M Cappola; P Robinson Journal: Biopharm Drug Dispos Date: 1999-09 Impact factor: 1.627
Authors: T Kredo; K Mauff; J S Van der Walt; L Wiesner; G Maartens; K Cohen; P Smith; K I Barnes Journal: Antimicrob Agents Chemother Date: 2011-09-26 Impact factor: 5.191
Authors: J Tarning; I Zongo; F A Somé; N Rouamba; S Parikh; P J Rosenthal; W Hanpithakpong; N Jongrak; N P J Day; N J White; F Nosten; J-B Ouedraogo; N Lindegardh Journal: Clin Pharmacol Ther Date: 2012-01-18 Impact factor: 6.875
Authors: Kay Seden; Sara Gibbons; Catia Marzolini; Jonathan M Schapiro; David M Burger; David J Back; Saye H Khoo Journal: PLoS One Date: 2017-03-23 Impact factor: 3.240
Authors: George O Adjei; Seth K Amponsah; Bamenla Q Goka; Christabel Enweronu-Laryea; Lorna Renner; Abdul Malik Sulley; Michael Alifrangis; Jorgen A L Kurtzhals Journal: Curr Ther Res Clin Exp Date: 2019-01-12
Authors: Yongjie Zhang; Shalenie P den Braver-Sewradj; Michiel W den Braver; Steven Hiemstra; Nico P E Vermeulen; Bob van de Water; Jan N M Commandeur; J C Vos Journal: Front Pharmacol Date: 2018-04-18 Impact factor: 5.810
Authors: Clifford G Banda; Fraction Dzinjalamala; Mavuto Mukaka; Jane Mallewa; Victor Maiden; Dianne J Terlouw; David G Lalloo; Saye H Khoo; Victor Mwapasa Journal: Antimicrob Agents Chemother Date: 2018-06-26 Impact factor: 5.191